Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC–IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study
Conclusions
Complete cytoreduction might mitigate the difference in response to neoadjuvant chemotherapy. The presence of RD at IDS is associated with worse survival outcomes.
Source: International Journal of Gynecological Cancer - Category: Cancer & Oncology Tags: Ovarian Cancer Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Italy Health | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Ovarian Cancer | Ovaries | Study